Clinical Trial Update: Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 study assessing the impact of hepatic impairment on the safety, tolerability, and pharmacokinetics of an experimental drug in obesity…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency
• Obesity

Drugs mentioned

• Experimental drug

Snippet

Sponsor: Pfizer | Conditions: Obesity, Hepatic Insufficiency | Phase 1 | Status: COMPLETED